Ocugen Completes Dosing in Clinical Trial
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) is a biotechnology firm dedicated to discovering, developing, and commercializing innovative gene and cell therapies. The Company has successfully completed dosing for the third cohort in its Phase 1/2 GARDian clinical trial involving OCU410ST (AAV-hRORA), a promising gene therapy candidate aimed at treating Stargardt disease.
What is Stargardt Disease?
Stargardt disease is a serious genetic eye condition that leads to retinal degeneration and vision loss, impacting around 100,000 people in the U.S. and Europe. It is the most prevalent form of inherited macular degeneration, typically causing progressive vision impairment due to the deterioration of photoreceptors in the macula, the central part of the retina. This condition often begins during childhood or adolescence, resulting in varying levels of vision loss.
Importance of the GARDian Clinical Trial
The completion of dosing in the third cohort represents a significant milestone in the trial's development. Dr. Huma Qamar, Chief Medical Officer at Ocugen, expressed optimism about the progress, stating, "With all patients dosed in cohort 3 (high dose), Phase 1 of the dose-escalation portion of the trial is complete. We will continue to advance the trial efficiently, working towards fulfilling an unmet medical need for Stargardt patients.”
Structure and Administration of the Trial
The GARDian clinical trial is designed as a multicenter, open-label, dose-ranging study that includes three dose levels: low dose (3.75×1010 vg/mL), medium dose (7.5×1010 vg/mL), and high dose (2.25×1011 vg/mL). So far, three subjects have received a single subretinal injection using the highest dose tested.
Promise of OCU410ST
Charles Wykoff, MD, PhD, the Director of Research at Retina Consultants of Texas and the lead investigator for this study, has highlighted the significant potential of OCU410ST. He stated, "OCU410ST is a novel modifier gene therapy that could provide a one-time treatment administered via subretinal injection within the operating room. The safety and tolerability profile of OCU410ST remains encouraging as the clinical trial progresses, guiding hope for those affected by Stargardt disease who currently lack FDA-approved treatment.”
Progress in Gene Therapy Solutions
Ocugen is committed to developing groundbreaking gene therapy solutions that aim to combat blindness and improve patient outcomes. The Company’s dedication to researching and advancing these therapies reflects its determination to deliver lasting benefits to those in need.
About OCU410ST and Its Development
OCU410ST utilizes an AAV delivery mechanism to effectively transport the RORA (RAR Related Orphan Receptor A) gene. This therapeutic strategy harnesses the Nuclear Hormone Receptor (NHR) RORA to regulate pathways associated with Stargardt disease, including lipofuscin accumulation, oxidative stress, inflammation, and cell survival networks.
Overview of the Company
Ocugen, Inc. is dedicated to discovering, developing, and commercializing innovative gene and cell therapies that enhance health and provide hope to patients globally. The Company is well-known for its pioneering modifier gene therapy platform, which has the potential to address multiple retinal diseases with a single therapeutic approach, while also advancing research in infectious diseases and orthopedic conditions.
Frequently Asked Questions
What is the GARDian clinical trial?
The GARDian clinical trial is a Phase 1/2 study that investigates the safety and efficacy of OCU410ST, a gene therapy designed for Stargardt disease.
Who is leading the clinical trial for OCU410ST?
The clinical trial is being led by Charles Wykoff, MD, PhD, who is a recognized authority in retinal research.
What is Stargardt disease?
Stargardt disease is a genetic eye disorder that leads to retinal degeneration and vision loss, primarily affecting central vision.
How many subjects received treatment in the trial?
Three subjects have received the highest tested dose of OCU410ST during the clinical trial.
How is the OCU410ST therapy administered?
OCU410ST is delivered through a single subretinal injection performed in an operating room setting.
